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Abstract
Introduction. – Glioblastoma is a highly malignant brain tumor with a high-invasive phenotype, so the prognosis is unfavorable, even in
response to multidisciplinary treatment strategies. Obviously, therefore, a better therapeutic strategy is needed. Resveratrol has been reported
to be one of the most potent chemopreventive agents inhibiting the cellular processes associated with tumor development, including initiation,
promotion, and progression.
Materials and methods. – In this study we used RT-PCR, western blot and SDS-zymography to investigate the effect of resveratrol on the
expression of genes and proteins involved in the extracellular matrix remodeling associated with tumor invasion in human cultured glioblas-
toma cells treated for 24, 48 and 72 h. We analyzed the expression of matrix metalloproteinase-2 (MMP-2), the main mediator of glioblastoma
invasiveness, and the Secreted Protein Acidic and Rich in Cysteine (SPARC), involved in the regulation of cell–matrix interactions.
Results. – Our results show a dose-related decrease of MMP-2 mRNA and protein levels 72 h after resveratrol treatment, and lower SPARC
gene and protein expression 72 h after resveratrol treatment. This indicates that resveratrol may influence the two major factors in the ECM
remodeling occurring with tumor invasion, suggesting it may have uses as a therapeutic agent for brain tumors.
© 2005 Elsevier SAS. All rights reserved.
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1. Introduction
Brain tumors are one of the leading causes of death among
young children and adults. Gliomas are the most common
primary brain tumors, accounting for more than 40% of all
central nervous system neoplasms [1]. Four major grades of
gliomas are defined, glioblastoma being a highly malignant
tumor typically affecting adults between 45 and 60 years of
age [2]. Patients with malignant gliomas have a poor progno-
sis on account of the tumor’s high-invasive capacity: they infil-
trate diffusely into regions of the normal brain rendering total
surgical removal impossible.
Tumor invasion partly depends on degradation of extracel-
lular matrix (ECM) components mediated by tumor cell-
secreted proteolytic enzymes such as matrix metalloprotein-
ases (MMPs), a family of zinc-dependent proteases that break
down ECM components [3,4]. The expression of MMPs in
gliomas has been demonstrated, correlating glioma invasive-
ness with proteolytic activity of MMPs [5–7]. Gelatinases,
particularly matrix metalloproteinase-2 (MMP-2), can be con-
sidered the prime factor in glioma invasiveness, since it can
break down the basement membrane ECM components such
as collagen type IV and laminin. MMP-2 expression also cor-
relates with the progression and the degree of malignancy of
gliomas [8,9].
Secreted Protein Acidic and Rich in Cysteine (SPARC) is
a glycoprotein that influences a number of biological pro-
cesses including cell differentiation, migration and prolifera-
tion. With its counter-adhesive properties, SPARC modu-
lates cell–matrix interactions [10–12], and therefore, may have
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a functional role in tumor cell invasion of adjacent brain tis-
sue. SPARC also takes part in proteolytic pathways by increas-
ing the expression of collagenase and MMP-9, and activating
MMP-2 [13]. This protein is frequently over-expressed in glio-
mas and its expression correlates with glioma invasion in vitro
and in vivo [14–16]. SPARC may be a marker of invading
cells.
The highly invasive phenotype of malignant gliomas means
that patients have a poor prognosis, even using multidisci-
plinary treatment strategies including surgery, radiotherapy
and chemotherapy [17,18]. Therefore, a better therapeutic
strategy for malignant brain tumors is needed urgently.
In the search for new antitumoral agents over the past years,
many plant extracts have been investigated. Resveratrol (trans-
3,4′,5-trihydrostilbene) is a polyphenol found in various fruits
and vegetables, and has many biological and pharmaceutical
properties [19–21]. It is reported to be one of the most potent
chemopreventive agents inhibiting cellular processes associ-
ated with tumor development, including initiation, promo-
tion, and progression [22,23]. However, the precise mecha-
nism of its anti-tumorigenic or chemopreventive activities is
not understood, and only a few reports deal with the treat-
ment of glioma with resveratrol [24,25].
Therefore, we designed this study to investigate the effect
of resveratrol on highly malignant gliomas, evaluating the
expression of genes and proteins involved in the mechanisms
leading to tumor invasion. We analyzed MMP-2 and SPARC
gene and protein expression in human cultured glioblastoma
cells.
2. Materials and methods
2.1. Cell culture
Three human glioblastoma MI-cell lines (T60, T63, GBM)
were obtained from biopsy specimens as described else-
where [26]. Cell lines were maintained by serial passages in
RPMI 1640 medium containing 10% heat-inactivated fetal
bovine serum (FBS) at 37 °C in a 5% CO2 atmosphere and
were used within the first 20 passages. Glioblastoma (grade
IV glioma) cells were cultured in RPMI supplemented with
10% FBS and antibiotics (10 U/ml penicillin, 10 mg/ml strep-
tomycin) at 37 °C in a humidified atmosphere containing 5%
CO2.
2.2. Resveratrol treatment
Resveratrol (trans-3,4′,5-trihydroxystilbene) was pur-
chased from Sigma. A 100 mM solution of resveratrol was
prepared in DMSO and stored at –20 °C. For treatment, this
solution was diluted in RPMI 1640 and added to culture
medium to the desired final concentrations (1 and 50 µM).
Untreated cultures (VH) received the same amount of the sol-
vent (DMSO 0.05%). VH and treated cells were incubated
for 24, 48 and 72 h. At these intervals the supernatants were
collected and cells were washed in PBS, trypsinized and har-
vested by centrifugation (100 × g, 5 min). Each cell line was
cultured in duplicate. Glioblastoma cell viability was deter-
mined by Trypan blue staining.
2.3. RT-PCR analysis
Total RNA was extracted by a modification of the guani-
dine isothiocyanate/phenol/chloroform method (Tri-Reagent,
Sigma). After DNase I digestion, 1 µg of total RNA was
reverse-transcribed in 20 µl final volume of reaction mix
(Promega). The following primers were used for RT-PCR:
GAPDH 5′-ATTCCATGGCACCGTCAAGGCT, 3′-TCAG-
GTCCACCACGACACGTT (571 bp); MMP-2 5′-CCTC-
TCCACTGCCTTCGATACACC, 3′-AGCATCTATTCTT
GGGCACCG (162 bp); SPARC 5′-ACCATGAGGGCC-
TGGATC, 3′-GGAGTGG ATTTAGATCACAAG (936 bp).
Amplification reactions were conducted in a final volume
of 25 µl containing 2.5 µl of cDNA, 200 µM of the four dNTPs,
100 pmol of each primer, and 2.5 U of Taq DNA polymerase
(EuroTaq, Euroclone). The RT-PCR protocols are listed in
Table 1. The RT-PCR products were resolved by electrophore-
sis in 1.5% agarose gels, stained with ethidium bromide and
quantified by densitometric analysis (Image Pro-Plus).
2.4. SDS-zymography
ProMMP-2 protein levels were assessed in the superna-
tants of cultured glioblastoma cells by SDS-zymography.
Supernatants were concentrated in an Amicon Y10 at 6500 ×
g for 15 min at 4 °C. The concentrated culture media were
mixed 3:1 with sample buffer, containing 10% SDS. Four µg
total proteins per sample were run under non-reducing/non-
denaturing conditions onto 7.5% polyacrylamide gel (SDS-
PAGE) co-polymerized with 1 mg/ml type I gelatin. The gels
were run at 4 °C. After SDS-PAGE, the gels were washed
twice in 2.5% Triton X-100 for 30 min each and incubated
overnight in a substrate buffer at 37 °C (Tris–HCl 50 mM,
CaCl2 5 mM, NaN3 0.02%, pH 7.5). The MMP gelatinolytic
activity was detected after staining the gels with Coomassie
brilliant blue R250, as clear bands on a blue background [27].
To confirm the identity of MMP gelatinolytic activity, puri-




Gene Protocol Cycles (n°)
MMP-2 Denaturation 94 °C 1 min 30
Annealing 60 °C 2 min
Elongation 72 °C 3 min
SPARC Denaturation 94 °C 1 min 32
Annealing 55 °C 1 min
Elongation 72 °C 1 min
GAPDH Denaturation 94 °C 30 s 25
Annealing 62 °C 1 min
Elongation 72 °C 1 min
+72 °C 10 min to finalize extension
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2.5. Western blot
Concentrated culture media (20 µg of total proteins) were
diluted in SDS-sample buffer, loaded on 10% SDS-
polyacrylamide gel, separated under reducing and denatur-
ing conditions at 80 V according to Laemmli [28], and trans-
ferred at 90 V to a nitrocellulose membrane in 0.025 M Tris,
192 mM glycine, 20% methanol, pH 8.3 [29]. After electrob-
lotting, the membranes were air dried and blocked for 1 h
After being washed in TBST, membranes were incubated for
1 h at room temperature in monoclonal antibody to SPARC
(1:100 in TBST, Novocastra Laboratories) and, after washing,
in HRP-conjugated rabbit anti-mouse serum (1:40,000 dilu-
tion, Sigma). Immunoreactive bands were revealed by the
Opti-4CN substrate (Bio Rad).
2.6. Statistical analysis
All tests were run in duplicate. Data from the two runs are
expressed as mean ± standard error (S.E.M.), and were ana-
lyzed by one-way analysis of variance (ANOVA) followed
by the Student-Neumann-Keuls test. P values less than
0.05 were considered significant.
3. Results
3.1. Cell viability and proliferation
Phase contrast microscopy of cultured human glioblas-
toma cells confirmed the heterogeneity of shape and of the
nucleus (Fig. 1a). There was a dose-related decrease of pro-
liferation in glioblastoma cells treated with either 1 or 50 µM
resveratrol (Fig. 1b).
3.2. Gene expression
The gene expression analysis is presented in Fig. 2. MMP-
2 mRNA levels tended to be lower 48 h after resveratrol, and
the reduction was significant, and dose-related, after 72 h
(15%, N.S. after 1 µM; 29%, P < 0.05 after 50 µM) (Fig. 2a).
SPARC gene expression tended to be dose-dependently down-
regulated with both doses at all three intervals (Fig. 2b).
3.3. SDS-zymography
SDS-zymography analysis was done on the supernatants
of glioblastoma cells cultured for 72 h. The zymogram con-
tained two lysis bands corresponding to proMMP-2 and
proMMP-9. Densitometric analysis of the proMMP-2 band
indicated a dose-related decrease of the inactive gelatinase A
72 h after resveratrol treatment (10%, N.S. after 1 µM; 18%,
P < 0.05 after 50 µM) (Fig. 3 a, b). ProMMP-9 levels were
unaffected by resveratrol treatment.
3.4. Western blot
Densitometric analysis of immunoreactive bands corre-
sponding to SPARC revealed that SPARC protein levels
tended to be decreased by resveratrol 72 h after treatment of
glioblastoma cells (Fig. 4 a, b).
4. Discussion
Resveratrol can cross the blood–brain barrier and is taken
up by brain tissue [30]. This is a further pointer to resvera-
trol’s potential in the therapy of brain tumors. The precise
mechanisms of the anti-carcinogenesis effect of resveratrol
remain largely unknown. It is partly attributable to its anti-
oxidant activity, but experimental evidence indicates that these
properties are related to the compound’s ability to cause cell-
cycle arrest in the G1 phase [31] or in the S-G2 phase transi-
tion, or to trigger apoptosis in a variety of cancer cell lines
[32–34].
This is consistent with our findings of a dose-related
decrease of glioblastoma cell proliferation, particularly evi-
dent 72 h after resveratrol treatment.
Since resveratrol exerts a blocking effect on all tumor
development phases, we analyzed this effect on the mecha-
nisms involved in tumor invasion in highly malignant glio-
mas. The physical processes of invasion involve disengage-
ment of the cells from their microenvironment, followed by
breakdown of the surrounding matrix, cell movement, and
Fig. 1. a) Microphotographs of cultured glioblastoma cells after hematoxylin–
eosin staining showing the heterogeneity of cellular shape and of the nucleus.
Bar: 100 µm. b) Time-dependent effect of resveratrol on cultured glioblas-
toma cell proliferation. Cells were plated in T-75 flasks (500,000 cells/flask)
and allowed to attach. Fresh medium containing 1 and 50 µM resveratrol
was added, and cells were counted at the times indicated. Glioblastoma cells
incubated with vehicle (VH) were used as controls. Each time point repre-
sents the mean ± S.E.M. of duplicate samples.
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re-establishment of the local environment at a new location.
This allows glioma cells at the tumor-invasive front to over-
come the ECM barrier, and to penetrate adjacent brain struc-
tures. Since this is accomplished by an ECM remodeling pro-
cess involving MMP-2 and SPARC [35–37], we investigated
MMP-2 and SPARC gene and protein expression in human
cultured glioblastoma cells treated with two different doses
of resveratrol. We used 1 µM resveratrol since a similar res-
veratrol concentration is reached in the plasma of rats after
oral administration of red wine [38]. The 50 µM concentra-
tion was not cytotoxic in a neuroblastoma cell line [39] and
almost completely inhibited lymphocyte cell proliferation
[40].
In our conditions resveratrol significantly lowered MMP-
2 mRNA levels in glioblastoma cells after 72 h. This pattern
is consistent with the results of the protein analysis, showing
significantly reduced proMMP-2 levels at the same interval.
Interestingly, the effects on both MMP-2 mRNA and protein
levels were dose-related 72 h after resveratrol.
Resveratrol was found to inhibit MMP-2 in human liver
fibroblasts [41], but the mechanism remains unknown. MMP-
2 gene expression requires translocation of the transcription
factor NF-kB to the nucleus [42,43] and since resveratrol has
been reported to prevent the activation of NF-kB [44], its effect
on MMP-2 gene expression is quite likely achieved through
this inhibition.
SPARC is a matricellular protein that mediates interac-
tions between cell and their extracellular environment. This
protein has a major role in the promotion of glioma cell inva-
sion, as confirmed by evidence that human glioma cells engi-
neered to over-express SPARC adopt an invasive phenotype
[16]. A further interesting role for SPARC in the promotion
of tumor progression has also recently been suggested [45]:
it may enable tumor cells to survive under the stressful con-
ditions that surround the tumor, such as nutrient restriction,
hypoxia and genomic instability. The expression of SPARC
by gliomas induces cellular survival in serum-free conditions
and the apoptotic rate of SPARC-expressing glioma cell lines
is reduced relative to control line, representing a mechanism
through which gliomas resist cell death [36]. SPARC, there-
fore, may be an important target for cancer therapy, as it is
involved in tumor invasion and resistance to apoptosis. Our
results show a tendency to dose-dependent down-regulation
of SPARC gene expression 24, 48 and 72 h after resveratrol
treatment. Moreover, 72 h after resveratrol treatment SPARC
protein levels tended to be lower in glioblastoma treated cells,
compared to VH.
Considered as a whole, our results show that resveratrol
influenced MMP-2 and SPARC expression in glioblastoma
cells. This suggests that the two major determinants in ECM
remodeling associated with tumor invasion may be a target
for resveratrol, suggesting it could serve in the therapy of
brain tumors. The results also contribute to our knowledge of
Fig. 2. Bar graphs showing steady-state mRNA levels of MMP-2 (a) and
SPARC (b) in cultured human glioblastoma cells at the times indicated. Chan-
ges in mRNA levels are expressed as normalized optical densities relative to
GAPDH mRNA. Values are mean ± S.E.M. * P < 0.05 vs. VH.
Fig. 3. a) Representative SDS-zymography showing two lysis bands consis-
tent with proMMP-2 and proMMP-9. Glioblastoma supernatants were elec-
trophoresed on 7.5% gels. 1: VH; 2: resveratrol 1 µM; 3: resveratrol 50 µM.
b) Bar graphs showing proMMP-2 levels after densitometric scanning of
lysis bands. Values are mean ± S.E.M. * P < 0.05 vs. VH.
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the mechanisms of the antitumor and chemopreventive poten-
tial of resveratrol, suggesting it may have some potential in
therapy.
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